Accordingly, the genetic profile is dominated by NFκB-activating mutations, predominantly in MYD88 and CD79B, which are enriched in ABC-DLBCL and, especially, primary central nervous system lymphoma (PCNSL), primary testicular lymphoma (PTL), and intravascular large B-cell lymphoma [26–28]. The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.